# QuidelOrtho share price today (QuidelOrtho Corporation, QDEL)

> QuidelOrtho Corporation's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. QDEL · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/qdel

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $14.09 (−47.8% in a year)
- Revenue (Jun 2026): $631 M (+2.8% on a year ago)
- Profit (Jun 2026): −$92.9 M
- Operating margin: −2.1% (−2.0 points on a year ago)
- ROE: −59%, FY25
- ROIC: 4.6%, against a 6.4% cost of capital: −1.8 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the QuidelOrtho share price today? QuidelOrtho Corporation's share price was $14.09 at the close on 3 November 2026. That is 12.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between $10 and $34, and at that close it sat 16% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 1 week in a row. Over the last 1 year the share price moved −54% while the S&P 500 moved +21%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does QuidelOrtho pay? QuidelOrtho Corporation pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is QuidelOrtho on? QuidelOrtho is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is QuidelOrtho profitable? QuidelOrtho Corporation posted a net loss of $92.9 M in the Jun 2026 quarter. The full FY25 year was a loss of $1.1 B. That loss is 14.7% of the quarter's revenue. The same quarter a year earlier lost $255 M. 11 of the last 12 reported quarters were loss-making. ## How much revenue does QuidelOrtho make, and is it growing? QuidelOrtho Corporation reported $631 M of revenue in the Jun 2026 quarter, +2.8% on the same quarter a year earlier. Over 3 years it has grown 17.1% a year on average. The last full year, FY25, came in at $2.7 B. The last four reported quarters add to $2.7 B. FY25 revenue was $2.7 B, −1.9% on the year before. Recent pace: the last four quarters grew −2.3% on average, against 17.1% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −2.5%, against −2.9% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does QuidelOrtho keep? QuidelOrtho Corporation's operating margin was −2.1% in the Jun 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Across 5 years it has been between 1.7% and 53.9%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −2.0 percentage points on the year while gross margin changed −1.3 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is QuidelOrtho's profit turning into cash? Over the last 2 years, 135% of QuidelOrtho Corporation's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $105 M of operating cash against −$1.1 B of profit. After $188 M of spending on assets, free cash was −$83.0 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does QuidelOrtho's cash go? QuidelOrtho Corporation does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $593 M on assets over the last 3 years. Averaged over those years that is 7.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $593 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is QuidelOrtho's P/E ratio, and how does it compare with its own history? QuidelOrtho Corporation has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values QuidelOrtho Corporation at 0.4× its FY25 revenue of $2.7 B. The P/E comes back here once profit turns positive. ## Is the QuidelOrtho business getting better or worse? QuidelOrtho Corporation's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does QuidelOrtho earn on its capital? QuidelOrtho Corporation earned a ROE of −59% in FY25. That is up from a low of −69% in FY24. Its return on capital used (ROIC) is 1.8 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −41.5% net margin and 0.47× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −41.5% net margin × 0.47× asset turnover × 3.00× leverage (assets divided by equity) ≈ −58.5% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 4.6% − 6.4% = −1.8 percentage points. The 6.4% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 4.6% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 2.4%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does QuidelOrtho have too much debt? QuidelOrtho Corporation has total debt of $3.1 B against shareholder equity of $1.8 B as of Jun 2026, so its debt is 1.73× its equity. Year by year, that ratio went from 0.07 in FY22 to 1.49 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the QuidelOrtho shareholding pattern? 21.2% of QuidelOrtho Corporation's tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 6.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is QuidelOrtho from balance-sheet trouble? For QuidelOrtho Corporation, the Z-score is 0.52. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 0.52 is inside the danger zone, so the balance sheet is a real risk. ## How does QuidelOrtho rank in its industry? There is no score against its industry: QuidelOrtho Corporation is not among the largest members shown in this industry comparison for Medical Devices. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is QuidelOrtho compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to QuidelOrtho in size? QuidelOrtho is the 42nd largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: SI-BONE, Inc., Integra LifeSciences Holdings Corporation and IRADIMED CORPORATION. Just below it: Bioventus Inc., AdaptHealth Corp. and Beta Bionics, Inc. ### Medical Devices companies close in size

1. [SI-BONE, Inc.](https://www.sectoralpha.in/us/stocks/sibn) $1.1 billion
2. [Integra LifeSciences Holdings Corporation](https://www.sectoralpha.in/us/stocks/iart) $1.1 billion
3. [IRADIMED CORPORATION](https://www.sectoralpha.in/us/stocks/irmd) $1 billion
4. QuidelOrtho Corporation $966 million
5. [Bioventus Inc.](https://www.sectoralpha.in/us/stocks/bvs) $920 million
6. [AdaptHealth Corp.](https://www.sectoralpha.in/us/stocks/ahco) $838 million
7. [Beta Bionics, Inc.](https://www.sectoralpha.in/us/stocks/bbnx) $821 million

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [Green Plains Inc.](https://www.sectoralpha.in/us/stocks/gpre) $967 million · Chemicals
2. [Immatics N.V.](https://www.sectoralpha.in/us/stocks/imtx) $965 million · Biotechnology
3. QuidelOrtho Corporation $962 million
4. [Fluence Energy, Inc.](https://www.sectoralpha.in/us/stocks/flnc) $962 million · Utilities - Renewable
5. [BUUU Group Limited](https://www.sectoralpha.in/us/stocks/buuu) $960 million · Specialty Business Services

## What else do people ask about QuidelOrtho? ### What were QuidelOrtho's latest quarterly results? QuidelOrtho Corporation reported revenue of $631 M and a net loss of $92.9 M for the Jun 2026 quarter. Earnings per share were −$1.36. The operating margin was −2.1%, 2.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is QuidelOrtho's market cap? QuidelOrtho Corporation's market capitalisation is $966 M at a stock price of $14.09. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is QuidelOrtho performing? QuidelOrtho Corporation's latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 3 November 2026). ### Will QuidelOrtho's stock price go up? This page does not forecast QuidelOrtho Corporation's stock price. What it shows instead: the stock price is $14.09. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Does QuidelOrtho have too much debt? Yes, QuidelOrtho Corporation has a lot of debt: its debt is 1.72× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Is QuidelOrtho's profit real cash? Yes, over the last 2 years, 135% of QuidelOrtho Corporation's reported profit came in as cash from operations. The latest year was lower at -9%, so the trend is worth watching. In FY25, operating cash was $105 M against reported profit of −$1.1 B. Most of that cash then goes into building new capacity. These are yearly figures (as of 3 November 2026). ### Where is QuidelOrtho in its business cycle? QuidelOrtho Corporation's FY25 operating margin was 4.5%, against a 5-year range of 1.7% to 53.9%: the low end of its own range, which is often where recoveries start. The latest quarter was −2.1%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the QuidelOrtho story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is QuidelOrtho a stock worth studying right now? What the numbers show: QuidelOrtho Corporation's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.